MétaCan
Menu
Back to cohort
Record W4389485135 · doi:10.1038/s41408-023-00946-z

Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database

2023· article· en· W4389485135 on OpenAlexafffundabout
Alissa Visram, Ana de la Torre, Darrell White, Jiandong Su, Esther Masih‐Khan, Michael Chu, Víctor H. Jiménez‐Zepeda, Arleigh McCurdy, Richard LeBlanc, Kevin Song, Hira Mian, Martha Louzada, Michaël Sébag, Daniel Bergström, Julie Stakiw, Tony Reiman, Rami Kotb, Muhammad Aslam, Christopher P. Venner, Rayan Kaedbey, Engin Gul, Donna Reece

Bibliographic record

VenueBlood Cancer Journal · 2023
Typearticle
Languageen
FieldMedicine
TopicMultiple Myeloma Research and Treatments
Canadian institutionsCanadian Institutes of Health ResearchUniversity of British ColumbiaMemorial University of NewfoundlandMcGill UniversityMcGill University Health CentreLondon Health Sciences CentreWestern UniversityHôpital Maisonneuve-RosemontPrincess Margaret Cancer CentreUniversity of CalgaryJuravinski Cancer CentreJewish General HospitalAlberta Cancer FoundationUniversité de MontréalQueen Elizabeth II Health Sciences CentreSaint John Regional HospitalBC Cancer AgencyCancerCare ManitobaOttawa HospitalDalhousie University
FundersPfizer CanadaPfizer
KeywordsMedicineInternal medicineMultiple myelomaRefractory (planetary science)CohortLenalidomideSalvage therapyBortezomibDaratumumabOncologySurgeryChemotherapy

Abstract

fetched live from OpenAlex

Multiple myeloma (MM) remains incurable despite the availability of novel agents. This multi-center retrospective cohort study used the Canadian Myeloma Research Group Database to describe real-world outcomes of patients withanti-CD38 monoclonal antibody (mAb) refractory MM subsequently treated with standard of care (SoC) regimens. Patients with triple class refractory (TCR) disease (refractory to a proteasome inhibitor, immunomodulatory drug, and anti-CD38 mAb) were examined as a distinct cohort. Overall, 663 patients had disease progression on anti-CD38 mAb therapy, 466 received further treatment (346 with SoC regimens were included, 120 with investigational agents on clinical trial and were excluded). The median age at initiation of subsequent SoC therapy of 67.9 (range 39.6-89.6) years with a median of 3 prior lines (range 1-9). The median PFS and OS from the start of subsequent therapy was 4.6 (95% CI 4.1-5.6) months and 13.3 (95% CI 10.6-16.6) months, respectively. The median PFS and OS of patients with TCR disease (n = 199) was 4.4 (95% CI 3.6-5.3) months and 10.5 (95% CI 8.5-13.8) months. Our results reinforce that real-world patients with relapsed MM, particularly those with TCR disease, have dismal outcomes. There remains an urgent unmet need for the development of and access to effective therapeutics for these patients.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.002
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesScience and technology studies
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.290
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0020.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0010.002
Science and technology studies0.0020.001
Scholarly communication0.0000.000
Open science0.0010.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.153
GPT teacher head0.418
Teacher spread0.266 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations12
Published2023
Admission routes3
Has abstractyes

Explore more

Same venueBlood Cancer JournalSame topicMultiple Myeloma Research and TreatmentsFrench-language works237,207